Addition of bortezomib to rituximab in relapsed or refractory follicular lymphoma results in small progression-free survival improvement

by: Nicola PocockAccording to the findings of a Phase III study published early online in the Lancet Oncology, the combination of bortezomib and rituximab is associated with a lower than expected improvement in progression-free survival (PFS) over rituximab monotherapy in the treatment of patients with FL that has relapsed following, or progressed during, previous therapy. The authors note that